Legacy Capital Wealth Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Legacy Capital Wealth Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$14.6K	Buy	+27,080	New	+$19.7K	0.01%	51

Other funds holding ADAP

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Legacy Capital Wealth Management's ADAP Position: Q4 2024 in Review

Legacy Capital Wealth Management opened a new position in Adaptimmune Therapeutics (ADAP) in Q4 2024: 27,080 shares worth $14.6K. The stake represents 0.01% of the portfolio and ranks #51 among its holdings.

80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

Legacy Capital Wealth Management held 27,080 shares of Adaptimmune Therapeutics worth $14.6K as of Q4 2024.
Adaptimmune Therapeutics was a new Legacy Capital Wealth Management position in Q4 2024.
Adaptimmune Therapeutics made up 0.01% of Legacy Capital Wealth Management's portfolio in Q4 2024, its #51 holding.
80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on Legacy Capital Wealth Management's 13F filing for Q4 2024, filed 4 Jun 2025.